Keep knowledgeable with free updates
Merely signal as much as the Prescription drugs sector myFT Digest — delivered on to your inbox.
The US imported a report $53bn of merchandise used within the prescription drugs and medical business in March as corporations rushed to construct stockpiles in case Donald Trump hits the sector with tariffs.
Imports of pharma merchandise soared about 160 per cent in March from the identical month the earlier yr, and virtually doubled from February, reaching the very best on Census Bureau information stretching again to 2002.
The push to buy completed merchandise and elements which are used to make them is likely one of the earliest indicators of how Trump’s sweeping tariffs on US buying and selling companions are reshaping world enterprise.
The US has not but introduced levies concentrating on the prescription drugs sector, however corporations are getting ready for the likelihood they may be imposed after the nation final month launched a nationwide safety overview on the topic.
The US president on Monday promised to make European international locations pay extra for medication, whereas calling on pharmaceutical corporations to decrease costs for American shoppers. A White Home official famous, nonetheless, that tariffs on pharma merchandise have been a “separate” matter.
The US and UK stated final week they might promptly negotiate “considerably preferential” tariff therapies on medication and elements. The pledge can be contingent on the end result of Washington’s prescription drugs sector probe and UK compliance with provide chain safety necessities.
Eire accounted for $28bn of the imports in March, up from $5.5bn in the identical interval the earlier yr. A number of US pharmaceutical corporations have manufacturing websites in Eire — lured partly by Dublin’s comparatively low company tax fee. The nation, which is the third-largest exporter of prescription drugs globally, has roughly 50 US Meals and Drug Administration-approved pharma and biopharma vegetation.
JPMorgan Chase’s Abiel Reinhart stated branded drug builders “will have the ability to use the import stockpile they’re constructing now to cushion the impression of tariffs whereas they construct out US manufacturing”.
Cuts to US company tax charges through the earlier Trump administration decreased among the incentive to fabricate in Europe, he stated, however added that “the quantity of manufacturing in Europe remains to be excessive owing to previous investments”.
A variety of US pharmaceutical teams have lately made bulletins about increasing home manufacturing. These embody Eli Lilly, which in February set out plans for $27bn of investment, whereas Johnson & Johnson stated in March that it will make investments greater than $55bn in 4 factories.
On a quarterly earnings name this month, Lilly’s chief government informed traders that “upon completion” of the corporate’s manufacturing plan, it “will have the ability to provide medicines for the US market completely from US services, in addition to enhance the quantity of medicines we export”.
Different US pharmaceutical corporations have careworn that they have already got a powerful home manufacturing presence and that they’ve arrange processes to answer risky commerce coverage.
Biogen, a big biotech group, stated in its first-quarter outcomes that it “operates a big manufacturing presence within the US”, whereas Pfizer’s chief monetary officer informed analysts that the corporate had arrange a “cross-functional workforce” to analyse potential outcomes within the present “fluid atmosphere”.
Merck chief government Rob Davis informed analysts that whereas the corporate’s “largest publicity” for tariffs was its blockbuster most cancers drug Keytruda, it had stock within the US to final all of 2025.
Business figures have warned on the impression of pharmaceutical tariffs, together with the chief government of Johnson and Johnson, who stated they might result in drug shortages.
The US presently has no tariffs on many prescription drugs due to a 1994 World Commerce Group commerce deal.
European prescription drugs corporations are additionally boosting their US investments in response to the tariff threats. AstraZeneca stated this month it was planning additional funding along with its 11 US manufacturing websites, together with shifting manufacture of Europe-made merchandise to the nation.
UK-listed GSK is planning tens of billions of {dollars} of funding in manufacturing and analysis and growth within the US over the subsequent 5 years.
Extra reporting by Jude Webber in Dublin
